Prostate cancer (PC) is the most common non-cutaneous cancer and the second leading cause of cancer-associated deaths among men.1 Since its discovery, prostate-specific antigen (PSA) remains the most widely used serum-based biomarker for PC prognostic assessment and treatment decisions. Here, KLK3 is linked to prostate carcinoma.